Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.
RayzeBio, Inc.
RayzeBio, Inc.
National Institutes of Health Clinical Center (CC)
RayzeBio, Inc.
National Institutes of Health Clinical Center (CC)
Crinetics Pharmaceuticals Inc.
Crinetics Pharmaceuticals Inc.
Cedars-Sinai Medical Center
M.D. Anderson Cancer Center
Hospices Civils de Lyon
CHU de Reims
Suez Canal University
Suez Canal University
Suez Canal University
Fox Chase Cancer Center
Wren Laboratories LLC
Hospices Civils de Lyon
Merck Sharp & Dohme LLC
Société Algérienne de Formation et de Recherche en Oncologie
British Columbia Cancer Agency
Sunnybrook Health Sciences Centre
Queen Mary University of London
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Advanced Accelerator Applications
Taproot Health
CHU de Quebec-Universite Laval
Hutchmed
AC Camargo Cancer Center
University Medical Center Groningen
Dana-Farber Cancer Institute
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Roswell Park Cancer Institute
SCRI Development Innovations, LLC
SCRI Development Innovations, LLC
Stanford University
European Institute of Oncology
University of Alabama at Birmingham
Dana-Farber Cancer Institute
Radio Isotope Therapy of America
H. Lee Moffitt Cancer Center and Research Institute
British Columbia Cancer Agency
British Columbia Cancer Agency
Brahms AG
Provectus Pharmaceuticals
Ipsen
University of Chicago
University of Iowa
Novartis
Amgen
British Columbia Cancer Agency